Patents by Inventor Carl Gustav Figdor
Carl Gustav Figdor has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230159702Abstract: The present invention is directed to nanofilaments for polymer brushes, to polymer brushes comprising the nanofilaments and methods of making the same. In particular, the invention provides water soluble nanofilaments which may be grafted to a surface and which may be functionalised with (bio)molecules.Type: ApplicationFiled: February 27, 2020Publication date: May 25, 2023Applicant: STICHTING RADBOUD UNIVERSITAIR MEDISCH CENTRUMInventors: Dion VOERMAN, Roelof HAMMINK, Martijn VERDOES, Carl Gustav FIGDOR
-
Patent number: 11286352Abstract: A process for the preparation of beads including a biocompatible hydrophobic polymer, a perfluorocarbon, polyvinylalcohol and optionally a metal compound, including the steps of: adding the perfluorocarbon and optionally the metal compound to a solution of the biocompatible hydrophobic polymer in a polar solvent to provide a first liquid mixture, adding the first liquid mixture to an aqueous solution of a biocompatible surfactant including polyvinylalcohol under sonication to obtain a second liquid mixture, a) maintaining the sonication of the second liquid mixture while cooling, b) evaporating the polar solvent from the second liquid mixture to obtain a suspension of beads including the biocompatible hydrophobic polymer, the perfluorocarbon and optionally the metal compound, c) separating the beads from the suspension and preparing a water suspension of the beads and d) freeze-drying the water suspension to obtain the beads, wherein the addition of the first liquid mixture to the biocompatible surfactant inType: GrantFiled: March 13, 2017Date of Patent: March 29, 2022Assignee: STICHTING RADBOUD UNIVERSITAIR MEDISCH CENTRUMInventors: Mangala Srinivas, Olga Koshkina, Carl Gustav Figdor, Ingrid Jolanda Monique De Vries
-
Patent number: 11185600Abstract: The present invention relates to contrast agent enhanced medical ultrasound imaging. In particular, the contrast agents provided are useful for cell imaging and cell therapy, as well as in vivo targeting, drug delivery and perfusion or vascular imaging applications. More specifically, it provides a particle comprising a fluorinated organic compound and a metal. Such particles may be advantageously employed in qualitative or quantitative imaging such as acoustic imaging including photoacoustic and ultrasound imaging, MRI imaging, such as 19F imaging, 1H imaging including T1 and T2 weighted imaging, SPECT, PET, scintigraphy, fluorescence imaging and optical coherence imaging and tomographic applications. This may then be employed in cell labeling, microscopy, histology or for imaging vasculature or perfusion in vivo and in vitro.Type: GrantFiled: September 14, 2013Date of Patent: November 30, 2021Assignee: STICHTING RADBOUD UNIVERSITAIR MEDISCH CENTRUMInventors: Carl Gustav Figdor, Ingrid Jolanda Monique De Vries, Mangala Srinivas, Luis Javier Cruz Ricondo, Christoffel Leendert De Korte
-
Patent number: 10350298Abstract: The present invention relates to protein constructs that comprise one or more peptides, proteins, factors, compounds or other components as further described herein that are linked to and/or are linked to each other via a helical polymeric backbone. The constructs of the invention are suitable for administration to a human or animal body and can be used for pharmaceutical purposes, for example, for immunotherapy, such as for treating cancer and for other immunological applications, as well as for other therapeutic, prophylactic and/or diagnostic purposes.Type: GrantFiled: July 7, 2011Date of Patent: July 16, 2019Assignees: Stichting Katholieke Universiteit, Radboud University Nijmegen Medical Centre, Stichting Katholieke Universiteit, meer in het bijzonder Radboud Universiteit NijmegenInventors: Alan Edward Rowan, Carl Gustav Figdor
-
Publication number: 20190077925Abstract: A process for the preparation of beads including a biocompatible hydrophobic polymer, a perfluorocarbon, polyvinylalcohol and optionally a metal compound, including the steps of: adding the perfluorocarbon and optionally the metal compound to a solution of the biocompatible hydrophobic polymer in a polar solvent to provide a first liquid mixture, adding the first liquid mixture to an aqueous solution of a biocompatible surfactant including polyvinylalcohol under sonication to obtain a second liquid mixture, a) maintaining the sonication of the second liquid mixture while cooling, b) evaporating the polar solvent from the second liquid mixture to obtain a suspension of beads including the biocompatible hydrophobic polymer, the perfluorocarbon and optionally the metal compound, c) separating the beads from the suspension and preparing a water suspension of the beads and d) freeze-drying the water suspension to obtain the beads, wherein the addition of the first liquid mixture to the biocompatible surfactant inType: ApplicationFiled: March 13, 2017Publication date: March 14, 2019Inventors: Mangala SRINIVAS, Olga KOSHKINA, Carl Gustav FIGDOR, Ingrid Jolanda Monique DE VRIES
-
Publication number: 20180185485Abstract: In the field of medical therapy, more in particular in the field of ablation therapy using ultrasound, such as high intensity focused ultrasound (HIFU), devices and methods are disclosed for enhancing the ablation effect of HIFU. More in particular, a polymeric particle is disclosed, including a polymer entrapping a liquid perfluorocarbon for use in high frequency ultrasound (HIFU) ablation therapy in a human or animal body, wherein the HIFU is focused in a focal region, wherein the ablation effect of the HIFU in the focal region is enhanced by administering the particles to the human or animal body, and the liquid perfluorocarbon does not undergo a phase change from liquid to gas during exposure to the HIFU.Type: ApplicationFiled: July 1, 2016Publication date: July 5, 2018Inventors: Mangala SRINIVAS, Carl Gustav FIGDOR, Ingrid Jolanda Monique DE VRIES
-
Publication number: 20150250905Abstract: The present invention relates to contrast agent enhanced medical ultrasound imaging. In particular, the contrast agents provided are useful for cell imaging and cell therapy, as well as in vivo targeting, drug delivery and perfusion or vascular imaging applications. More specifically, it provides a particle comprising a fluorinated organic compound and a metal. Such particles may be advantageously employed in qualitative or quantitative imaging such as acoustic imaging including photoacoustic and ultra-sound imaging, MRI imaging, such as 19F imaging, 1H imaging including T1 and T2 weighted imaging, SPECT, PET, scintigraphy, fluorescence imaging and optical coherence imaging and tomographic applications. This may then be employed in cell labeling, microscopy, histology or for imaging vasculature or perfusion in vivo and in vitro.Type: ApplicationFiled: September 14, 2013Publication date: September 10, 2015Inventors: Carl Gustav Figdor, Ingrid Jolanda Monique De Vries, Mangala Srinivas, Luis Javier Cruz Ricondo
-
Publication number: 20130202548Abstract: The present invention relates to protein constructs that comprise one or more peptides, proteins, factors, compounds or other components as further described herein that are linked to and/or are linked to each other via a helical polymeric backbone. The constructs of the invention are suitable for administration to a human or animal body and can be used for pharmaceutical purposes, for example, for immunotherapy, such as for treating cancer and for other immunological applications, as well as for other therapeutic, prophylactic and/or diagnostic purposes.Type: ApplicationFiled: July 7, 2011Publication date: August 8, 2013Applicant: Stichting Katholieke Universiteit of NijmegenInventors: Alan Edward Rowan, Carl Gustav Figdor
-
Patent number: 8333725Abstract: The invention relates to a device for separating a bodily fluid, in particular blood platelet concentrate, into fractions under centrifugal force. The device comprises a flexible container system which comprises at least a first container for the fluid to be separated and a second container for a separated fraction, wherein the containers are mutually connected using a connecting conduit for a fluid, wherein a widened portion is arranged in the connecting conduit between the first and second container, wherein during use a detectable separating layer is created in the widened portion. The invention also relates to a flexible container system intended for the device, a method for separating blood platelet concentrate into fractions under centrifugal force, and a blood platelet concentrate with low leukocyte content.Type: GrantFiled: June 27, 2007Date of Patent: December 18, 2012Assignee: Klip Consultancy B.V.Inventors: Evert Jan Klip, Carl Gustav Figdor
-
Publication number: 20120076827Abstract: The invention relates to a method for providing an activated antigen-presenting cell or a composition that comprises at least one activated antigen-presenting cell, which method at last comprises the steps of providing a composition that comprises at least one antigen-presenting cell and contacting said composition with a vaccine. Suitably, the at least one dendritic cell is brought into a state in which it is capable of stimulating T-cells and/or a T-cell mediated response.Type: ApplicationFiled: January 22, 2010Publication date: March 29, 2012Applicant: Stichting Katholieke Universiteit Radboud University Nijmegen Medical CentreInventors: Ingrid Jolanda Monique de Vries, Carl Gustav Figdor, Daniel Benitez Ribas
-
Patent number: 8105599Abstract: The present invention relates to the use of a compound that binds to a C-type lectin on the surface of a dendritic cell, in the preparation of a composition for modulating, in particular reducing, the immune response in an animal, in particular a human or another mammal. The composition in particular modulates the interactions between a dendritic cell and a T-cell, more specifically between a C-type lectin on the surface of a dendritic cell and an ICAM receptor on the surface of a T-cell. The compositions can be used for preventing/inhibiting immune responses to specific antigens, for inducing tolerance, for immunotherapy, for immunosuppression, for the treatment of autoimmune diseases, and the treatment of allergy. The compound that binds to a C-type lectin is preferably chosen from mannose, fucose, plant lectins, antibiotics, sugars, proteins or antibodies against C-type lectins. The invention also relates to such antibodies.Type: GrantFiled: July 23, 2003Date of Patent: January 31, 2012Assignee: Katholieke Universiteit NijmegenInventors: Carl Gustav Figdor, Teunis Bernard Herman Geijtenbeek, Yvette Van Kooyk, Ruurd Torensma
-
Patent number: 8075900Abstract: The present invention is concerned with cancer treatment and diagnosis, especially with melanoma associated peptide analogues with improved immunogenicity, epitopes thereof; vaccines against melanoma, tumor infiltrating T lymphocytes recognizing the antigen and diagnostics for the detection of melanoma and for the monitoring of vaccination. The peptides according to the invention can be exploited to elicit native epitope-reactive Cm. Usage of the peptides with improved immunogenicity may contribute to the development of CTL-epitope based vaccines in viral disease and cancer.Type: GrantFiled: December 6, 2010Date of Patent: December 13, 2011Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Carl Gustav Figdor, Gosse Jan Adema
-
Patent number: 8058400Abstract: The present invention relates to the use of a compound that binds to a C-type lectin on the surface of a dendritic cell, in the preparation of a composition for modulating, in particular reducing, the immune response in an animal, in particular a human or another mammal. The composition in particular modulates the interactions between a dendritic cell and a T-cell, more specifically between a C-type lectin on the surface of a dendritic cell and an ICAM receptor on the surface of a T-cell. The compositions can be used for preventing/inhibiting immune responses to specific antigens, for inducing tolerance, for immunotherapy, for immunosuppression, for the treatment of autoimmune diseases, and the treatment of allergy. The compound that binds to a C-type lectin is preferably chosen from mannose, fucose, plant lectins, antibiotics, sugars, proteins or antibodies against C-type lectins. The invention also relates to such antibodies.Type: GrantFiled: October 22, 2007Date of Patent: November 15, 2011Assignee: Katholieke Universiteit NijmegenInventors: Carl Gustav Figdor, Teunis Bernard H. Geijtenbeek, Yvette Van Kooyk, Ruurd Torensma
-
Publication number: 20110135675Abstract: The present invention is concerned with cancer treatment and diagnosis, especially with melanoma associated peptide analogues with improved immunogenicity, epitopes thereof; vaccines against melanoma, tumor infiltrating T lymphocytes recognizing the antigen and diagnostics for the detection of melanoma and for the monitoring of vaccination. The peptides according to the invention can be exploited to elicit native epitope-reactive Cm. Usage of the peptides with improved immunogenicity may contribute to the development of CTL-epitope based vaccines in viral disease and cancer.Type: ApplicationFiled: December 6, 2010Publication date: June 9, 2011Applicant: The United States of America, as represented by Secretary, Department of Health and Human ServiceInventors: Carl Gustav Figdor, Gosse Jan Adema
-
Patent number: 7846450Abstract: The present invention is concerned with cancer treatment and diagnosis, especially with melanoma associated peptide analogues with improved immunogenicity, epitopes thereof, vaccines against melanoma, tumor infiltrating T lymphocytes recognizing the antigen and diagnostics for the detection of melanoma and for the monitoring of vaccination. The peptides according to the invention can be exploited to elicit native epitope-reactive Cm. Usage of the peptides with improved immunogenicity may contribute to the development of CTL-epitope based vaccines in viral disease and cancer.Type: GrantFiled: December 18, 2008Date of Patent: December 7, 2010Assignee: United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Carl Gustav Figdor, Gosse Jan Adema
-
Patent number: 7691591Abstract: The C-type lectin DC-SIGN is absent in normal synovium but is highly expressed by CD68 positive macrophages in the synovium of rheumatoid arthritis patients. Accordingly, rheumatoid arthritis is diagnosed or treated by, respectively, assaying or blocking DC-SIGN. This can be accomplished by the use of agents, e.g., antibodies, which bind specifically to DCSIGN. Agents that bind to ICAM-3 are used to block inhibition of activation of macrophages by DC-SIGN-ICAM-3 interaction and cause inhibition of rheumatoid arthritis symptoms.Type: GrantFiled: September 19, 2003Date of Patent: April 6, 2010Assignee: Stichting Katholieke UniversiteitInventors: Carl Gustav Figdor, Ruurd Torensma, Petrus Leonardus Everardus Maria Van Lent, Wim B. Van Den Berg
-
Publication number: 20090286221Abstract: The invention relates to a device for separating a bodily fluid, in particular blood platelet concentrate, into fractions under centrifugal force. The device comprises a flexible container system which comprises at least a first container for the fluid to be separated and a second container for a separated fraction, wherein the containers are mutually connected using a connecting conduit for a fluid, wherein a widened portion is arranged in the connecting conduit between the first and second container, wherein during use a detectable separating layer is created in the widened portion. The invention also relates to a flexible container system intended for the device, a method for separating blood platelet concentrate into fractions under centrifugal force, and a blood platelet concentrate with low leukocyte content.Type: ApplicationFiled: June 27, 2007Publication date: November 19, 2009Applicant: Klip Consultancy B.V.Inventors: Evert Jan Klip, Carl Gustav Figdor
-
Publication number: 20090285839Abstract: Dendritic cells (DC) that express the type II C-type lectin DC-SIGN (CD209) are located in the submucosa of tissues, where they mediate HIV-1 entry. Interestingly, the pathogen Candida albicans, the major cause of hospital-acquired fungal infections, is found at similar sites. Here it is demonstrated that DC-SIGN is able to bind Candida albicans both in DC-SIGN transfected cell lines and in human monocyte derived DC. Moreover, in immature DC, DC-SIGN is able to internalize Candida in specific DC-SIGN enriched vesicles, distinct from those containing the mannose receptor (MR; CD206), which is another Candida receptor on DC. Together, these results demonstrate that C. albicans has two major receptors on human monocyte derived DC, these receptors being DC-SIGN and MR. Targeting of DC-SIGN offers novel opportunities to combat chronic forms of candidiasis.Type: ApplicationFiled: April 28, 2009Publication date: November 19, 2009Applicant: Stichting Katholieke UniversiteitInventors: Carl Gustav Figdor, Ruurd Torensma
-
Publication number: 20090232839Abstract: The present invention is concerned with cancer treatment and diagnosis, especially with melanoma associated peptide analogues with improved immunogenicity, epitopes thereof, vaccines against melanoma, tumor infiltrating T lymphocytes recognizing the antigen and diagnostics for the detection of melanoma and for the monitoring of vaccination. The peptides according to the invention can be exploited to elicit native epitope-reactive Cm. Usage of the peptides with improved immunogenicity may contribute to the development of CTL-epitope based vaccines in viral disease and cancer.Type: ApplicationFiled: December 18, 2008Publication date: September 17, 2009Applicant: THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OFInventors: Carl Gustav Figdor, Gosse Jan Adema
-
Patent number: 7541032Abstract: Dendritic cells (DC) that express the type II C-type lectin DC-SIGN (CD209) are located in the submucosa of tissues, where they mediate HIV-1 entry. Interestingly, the pathogen Candidaalbicans, the major cause of hospital-acquired fungal infections, is found at similar sites. Here it is demonstrated that DC-SIGN is able to bind Candida albicans both in DC-SIGN transfected cell lines and in human monocyte derived DC. Moreover, in immature DC, DC-SIGN is able to internalize Candida in specific DC-SIGN enriched vesicles, distinct from those containing the mannose receptor (MR; CD206), which is another Candida receptor on DC. Together, these results demonstrate that C. albicans has two major receptors on human monocyte derived DC, these receptors being DC-SIGN and MR. Targeting of DC-SIGN offers novel opportunities to combat chronic forms of candidiasis.Type: GrantFiled: September 19, 2003Date of Patent: June 2, 2009Assignee: Stichting Katholieke UniversiteitInventors: Carl Gustav Figdor, Ruurd Torensma